Venus Remedies Secures In-Licensing Rights to Develop, Commercialize MET-X in India

MT Newswires Live

2025/02/25

Venus Remedies (NSE:VENUSREM, BOM:526953) has secured exclusive in-licensing rights from UK-based anti-infectives specialist Infex Therapeutics to develop and commercialize MET-X in India, according to a Tuesday filing to the Indian stock exchanges.

Under the terms of the agreement, Venus Remedies will begin with the first phase involving healthy volunteers in lndia, evaluating MET-X in combination with meropenem.

Following this, the focus will shift to the second and third phase trials targeting drug resistant complicated urinary tract infections in prevalent hospital settings.

Shares of the company were up 2% in recent trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514326080"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514326080\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514326080?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 13:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514326080","market":"nz","top_or_hot":-1,"title":"Venus Remedies Secures In-Licensing Rights to Develop, Commercialize MET-X in India","media":"MT Newswires Live","content":"<html><body><p> Venus Remedies (NSE:VENUSREM, BOM:526953) has secured exclusive in-licensing rights from UK-based anti-infectives specialist Infex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to develop and commercialize MET-X in India, according to a Tuesday filing to the Indian stock exchanges.</p><p>Under the terms of the agreement, Venus Remedies will begin with the first phase involving healthy volunteers in lndia, evaluating MET-X in combination with meropenem.</p><p>Following this, the focus will shift to the second and third phase trials targeting drug resistant complicated urinary tract infections in prevalent hospital settings.</p><p>Shares of the company were up 2% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Venus Remedies Secures In-Licensing Rights to Develop, Commercialize MET-X in India</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVenus Remedies Secures In-Licensing Rights to Develop, Commercialize MET-X in India\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-25 13:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Venus Remedies (NSE:VENUSREM, BOM:526953) has secured exclusive in-licensing rights from UK-based anti-infectives specialist Infex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to develop and commercialize MET-X in India, according to a Tuesday filing to the Indian stock exchanges.</p><p>Under the terms of the agreement, Venus Remedies will begin with the first phase involving healthy volunteers in lndia, evaluating MET-X in combination with meropenem.</p><p>Following this, the focus will shift to the second and third phase trials targeting drug resistant complicated urinary tract infections in prevalent hospital settings.</p><p>Shares of the company were up 2% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MET","symbol_name":"大都会人寿","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514326080","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514326080","pubTimestamp":1740462660,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Venus Remedies (NSE:VENUSREM, BOM:526953) has secured exclusive in-licensing rights from UK-based anti-infectives specialist Infex Therapeutics to develop and commercialize MET-X in India, according t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MET":"大都会人寿","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4162":"人寿与健康保险","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H"},"translate_title":"Venus Remedies获得在印度开发和商业化MET-X的许可权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MET":1},"content_text":"Venus Remedies (NSE:VENUSREM, BOM:526953) has secured exclusive in-licensing rights from UK-based anti-infectives specialist Infex Therapeutics to develop and commercialize MET-X in India, according to a Tuesday filing to the Indian stock exchanges.Under the terms of the agreement, Venus Remedies will begin with the first phase involving healthy volunteers in lndia, evaluating MET-X in combination with meropenem.Following this, the focus will shift to the second and third phase trials targeting drug resistant complicated urinary tract infections in prevalent hospital settings.Shares of the company were up 2% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}